Drug
Precision and Immune-Based Therapies
SpyGlass completes enrollment in trial of long-term drug delivery platform for glaucoma
SpyGlass Pharma has completed enrollment in its phase 1/2 clinical trial evaluating a long-term drug delivery platform of bimatoprost for glaucoma and ocular hypertension, according to a press release.
One in four adults would use a weight loss drug without consulting a physician
A quarter of adults would consider using an injectable weight loss drug without consulting a health care provider, according to the results of a survey from The Ohio State University Wexner Medical Center.
Akebia readies launch of anemia drug Vafseo; planning talks with FDA on pre-dialysis use
As Akebia Therapeutics announced plans to launch its anemia drug Vafseo to the dialysis community, company officials said they intend to work with the FDA for more testing of the drug for the pre-dialysis market.
Most Americans unsure of how to respond during a drug overdose
Most Americans feel they would not be ready to help in the event of a drug overdose, according to the results of a recent survey.
CDC: Drug overdose deaths decreased in 2023
Drug overdose deaths in the United States decreased in 2023 for the first time in half a decade, preliminary CDC data showed.
Adverse drug reactions seen as ‘major cause of hospitalization’ in patients with CKD
Adverse drug reactions make up a major cause of hospitalization in patients with chronic kidney disease where lower eGFR is a risk factor, according to published data.
FDA grants orphan drug designation to AP303 for autosomal dominant PKD
The FDA has granted orphan drug designation to AP303 for the treatment of autosomal dominant polycystic kidney disease.
Akebia receives FDA approval for anemia drug Vafseo
Akebia Therapeutics Inc. has received FDA approval for its oral anemia drug Vafseo for treating anemia in adults with end-stage kidney disease on dialysis for at least 3 months.
FDA grants orphan drug designation to felzartamab
The FDA has granted orphan drug designation for felzartamab, an antibody-mediated rejection therapy for kidney transplant recipients, according to a press release.